Lucinactant
Surfaxin (lucinactant) is an unknown pharmaceutical. Lucinactant was first approved as Surfaxin on 2012-03-06.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lucinactant
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SURFAXIN | Windtree Therapeutics | N-021746 DISCN | 2012-03-06 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | 1 | 7 | 5 | 4 | 17 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | 2 | ||
| Colonoscopy | D003113 | — | — | — | 2 | — | 2 | ||
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | 1 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 2 | 1 | 2 | — | 2 | 7 |
| Opioid-induced constipation | D000079689 | — | — | 4 | — | 1 | 5 | ||
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | — | — | 1 | |
| Treatment outcome | D016896 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LUCINACTANT |
| INN | — |
| Description | Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome. It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.
|
| Classification | Small molecule |
| Drug class | pulmonary surfactants; tachykinin (neurokinin) receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 825600-90-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1963685 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB04897 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 225 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,750 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more